Skip to main content

Deutsche Bank Remains a Sell on AstraZeneca (AZN)

Tipranks - Tipranks - Thu Nov 13, 2025

Deutsche Bank analyst Emmanuel Papadakis maintained a Sell rating on AstraZeneca today and set a price target of £105.00.

Meet Your ETF AI Analyst

According to TipRanks, Papadakis is a 4-star analyst with an average return of 3.7% and a 53.29% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Sanofi, and Novartis AG.

Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of p14,197.23.

See Insiders’ Hot Stocks on TipRanks >>

Based on AstraZeneca’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of p14.84 billion and a net profit of p2.52 billion. In comparison, last year the company earned a revenue of p12.98 billion and had a net profit of p1.93 billion

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.

Read More on GB:AZN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).